High-dose melphalan followed by autograft employing non-cryopreserved peripheral blood progenitor cells in children

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
N JonesR Marcus

Abstract

High-dose chemotherapy followed by autologous bone marrow transplantation (ABMT) enables dose escalation in the treatment of childhood malignancies. Here we report our experience of using peripheral blood progenitor cells (PBPC) to restore haematopoiesis in five children using a simple cell mobilising regime and non-cryopreservation of the harvests. Cells were mobilised using cyclophosphamide and granulocyte colony stimulating factor. Each patient underwent only two leukaphereses, the product being stored before use at 4 degrees C. Successful autologous PBPC transplantation was achieved with melphalan conditioning chemotherapy and re-infusion of the total progenitor cell product. No colony stimulating factors were administered after transplantation. The median numbers of mononuclear cells collected per patient was 10.0 x 10(8)/kg (range 8.13-19.44) and CFU-GM 57.6 x 10(4)/kg (range 10.4-178.85). All patients subsequently engrafted with the median number of days to a neutrophil count > 0.5 x 10(9)/l being 11 (range 10-16), and to a platelet count > 50 x 10(9)/l being 14 (range 12-31). The median number of in-patient days was only 20 (range 19-30). The median demand for blood was 2 units (range 1-2), and platelets 4 units (range ...Continue Reading

References

Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C A Uyl-de GrootF F Rutten
Mar 1, 1994·Archives of Disease in Childhood·P L MitchellC R Pinkerton
Jan 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R LadensteinC R Pinkerton

❮ Previous
Next ❯

Citations

Feb 20, 2003·Journal of Hematotherapy & Stem Cell Research·Fransien de BoerGerrit J Schuurhuis
May 1, 1996·Annals of Hematology·G HechlerK Havemann
Apr 19, 2003·Transfusion·Allison HubelJeffrey McCullough
Oct 28, 2003·Cytotherapy·A HubelJ McCullough
Mar 23, 2010·Transfusion Medicine Reviews·Erwin F Strasser, Reinhold Eckstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.